Physician profile
Emily Drinkward
NPI 1770298267
$4,982.68
in general payments reported to CMS, 2019-2025
18 companies · $3,723 in 2025
The $3,723 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,260 · 2025: $3,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,819 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,818.84 |
| Education | $163.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,054.48 | 2024-2025 | |
| Glaxosmithkline, LLC. | $883.89 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $825.00 | 2024-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.29 | 2024-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $309.93 | 2024-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $269.75 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $198.62 | 2024-2025 | Winrevair |
| Insmed, INC. | $188.22 | 2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $105.57 | 2025 | Acthar |
| Verona Pharma, INC. | $84.04 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $69.64 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $38.50 | 2024-2025 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $33.77 | 2024 | |
| Pfizer INC. | $27.86 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $24.63 | 2025 | Yupelri |
| Lilly USA, LLC | $24.14 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $17.55 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Drinkward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.